Navigation Links
Gardasil (Cervical Cancer) - Analysis and Forecasts to 2020
Date:10/18/2011

pth analysis of Gardasil including efficacy, safety, pricing, competition and other details which influence its sales potential

- Detailed sales forecasts for 2006-2020 for Gardasil in the US and EU5

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of competition by understanding the changing competitive landscape

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of the drug's performance

- Examine the historical sales performance of a drug in seven major markets

- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Introduction 4

2.1 Cervical Cancer Vaccines Market 4

2.2 Epidemiology 4

2.3 Etiology 6

2.3.1 HPV Infections 6

2.3.2 Lack of Regular Papanicolaou (pap) Tests 7

2.3.3 Smoking 7

2.3.4 Sexual History 8

2.3.5 Birth Control Pills 8

2.4 GlobalData Report Guidance 8

3 Cervical Cancer Vaccines: Market Characterization 9

3.1 Cervical Cancer Vaccines Market 9

3.2 Drivers and Challenges for the Cervical Cancer Market 9

3.2.1 Drivers for Cervical Cancer Vaccine Market 9

3.2.2 Challenges for Cervical Cancer Vaccines 10

4 Gardasil (human papillomavirus vaccine(types6,11,16,18)) 11

4.1 Introduction 11

4.2 Human Papillomavirus Vaccine (HPV) 11

4.3 Mechanism of Action 11

4.4 Clinical Studies of Gardasil 11

4.4.1 Phase I and II trial 11

4.4.2 Phase III trial 12

4.5 Factors Affecting Sales 12

4.5.1 Cervical Cancer Market 12

4.5.2 Better Efficacy 13

4.5.3 Wide Disease Coverage
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA: Gardasil Approved to Prevent Anal Cancer
2. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
5. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
6. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
7. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
8. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
11. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 Company ... programming expertise to big data, aerospace and defense, ... eInfochips, a leading engineering R&D services company, today ... NVIDIA GPU-powered solutions for aerospace and defense ... (HPC), industrial , and visual ...
(Date:7/29/2014)... Israel , July 30, 2014 /PRNewswire/ ... Premier, Stockholm : "IMNP."; "Immune" or ... screening of patients for a Phase II proof of ... bertilimumab in the treatment of moderate to severe bullous ... will receive two bertilimumab infusions, at a dose of ...
(Date:7/29/2014)... Amgen (NASDAQ: AMGN ) today announced financial ... include: , Total revenues increased 11 percent to ... by strong performance across the portfolio, particularly Enbrel ® ... (denosumab) and XGEVA ® (denosumab). , Adjusted ... revenues and a significant increase in the profitability of ...
Breaking Medicine Technology:eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
(Date:7/30/2014)... (PRWEB) July 30, 2014 BuyCBDOnline.co ... infused products, is pleased to announce that it is ... selection of top quality products available for immediate shipping. ... still in it's infancy stages," site founder Jason Liss ... already a wide variety of unique products that are ...
(Date:7/30/2014)... 2014 The Independent Woman , ... holding 5 free financial workshops in the San Francisco ... goal of these workshops is our collective success, linking ... financial empowerment. , These workshops were designed by women, ... successful investor, entrepreneur, and bestselling author (Rich Woman and ...
(Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
(Date:7/30/2014)... According to the Yeast Infection No More book ... that will help candida sufferers get rid of their ... uncovers to readers the truth about yeast infection and the ... people will discover natural and safe remedies to relieve symptoms ... and irritation of the vagina or vulva. , Vkool ...
(Date:7/30/2014)... 30, 2014 My Clients Plus ... 80 different electronic therapy note templates. Healthcare providers ... other computing devices all while meeting the HIPPA ... electronic medial records (EMR) consist of psychological intake ... essential categories. SOAP and DAP note formats ...
Breaking Medicine News(10 mins):Health News:Delicious, Unique CBD-Rich Hemp Oil Product Debuts from BuyCBDOnline.co 2Health News:Delicious, Unique CBD-Rich Hemp Oil Product Debuts from BuyCBDOnline.co 3Health News:The Independent Woman is Coming to the San Francisco Area in August - Women Helping Women Reach Their Financial Goals 2Health News:The Independent Woman is Coming to the San Francisco Area in August - Women Helping Women Reach Their Financial Goals 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 2Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 4Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:My Clients Plus Announces Over 80 Online Therapy Notes to Help Healthcare Providers Go Paperless 2
... reports of persistent,recent-onset symptoms linked to ovarian cancer ... full quickly and abdominal bloating -- when,combined with ... detection of,ovarian cancer by 20 percent, according to ... Center published online today in CANCER., Research ...
... inflammatory rheumatic disease, associated with stiffening of the vertrebral ... diagnosed in Germany, but milder forms of the disease ... Dr. Roland R. Wick, with Dr. Elke A. Nekolla, ... Dr. Wolfgang Gssner have conducted a long-term follow-up study ...
... Oral cannabis may even cause increased sensitivity in certain ... -- Oral cannabis (a form of medical marijuana) was ... actually increased sensitivity to some other kinds of discomfort, ... , Their study included 18 healthy women who ...
... might extend the effectiveness of clot-busting tPA, researchers say ... weapon against cancer might also boost stroke patients, survival, ... "wonder drug" against cancers such as chronic myelogenous leukemia ... boost the effectiveness and limit the side effects of ...
... More younger people than before are expected to ... acid in 2008, according to Millennium Research Group, ... Group (MRG),conducted a detailed survey focused on facial ... conference in San Antonio, Texas.,Over 60 US-based dermatologists ...
... $0.96 to $0.97 - - ... - Announces Additional ... Nash Corporation,(Nasdaq: KNSY ) today updated and expanded its previously announced ... to,include earnings per share estimates. In addition, the Company provided an,outlook for ...
Cached Medicine News:Health News:Symptom Screening Plus a Simple Blood Test Equals a 20 Percent Jump in Early Detection of Ovarian Cancer 2Health News:Symptom Screening Plus a Simple Blood Test Equals a 20 Percent Jump in Early Detection of Ovarian Cancer 3Health News:Increased cancer risk following the use of radioactive Radium-224 in the therapy 2Health News:Medical Pot Ineffective as Acute Pain Treatment 2Health News:Cancer Drug Gleevec Could Fight Stroke 2Health News:Cancer Drug Gleevec Could Fight Stroke 3Health News:Younger Patients Seeking More Aesthetic Treatments 2Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 2Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 3Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 4Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 5Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 6Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 7Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 8Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 9
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: